References
- Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 1998; 39: 14s–20s
- Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 1993; 34: 689–94
- Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendorp HM, Bradley EW, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody, immunoconjugates and Radiopharmaceuticals 1990; 3: 213–33
- Hindorf C, Lindén O, Tennvall J, Wingårdh K, Strand S-E. Time dependence of activity concentration ratio of red marrow to blood and implications for red marrow dosimetry. Cancer supplement 2002; 94: 1235–9
- Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Nucl Med Biol 1989; 16: 553–9
- Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 2000; 27: 2150–64
- Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy. J Nucl Med 2002; 43: 1245–53
- Lindén O, Tennvall J, Cavallin-Ståhl E, Darte L, Garkavij M, Lindner K-J, et al. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 1999; 5: 3287s–91s
- Stabin MG. MIRDOSE: Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. J Nucl Med 1996; 37: 538–46
- Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 1981; 26: 389–400
- Sgouros G, Jureidini IM, Scott AM, Graham MC, Larson SM, Scheinberg DA. Bone Marrow Dosimetry: Regional variability of marrow-localizing antibody. J Nucl Med 1996; 37: 695–8
- Seldin DW. Techniques for Using Bexxar for the Treatment of Non-Hodgkin's Lymphoma. J Nucl Med Technol 2002; 30: 109–14
- Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol 2003; 30: 31–8